joint pain with glp 1 Semaglutide helps Knee Pain? New study says yes GLP-1 therapy is changing the

Comment on SGLT2 inhibitors, and how they work beyond the glucosuric effect

P = 0.06) ( The reported CV benefits were not associated with an increase in risk of severe hypoglycemia, retinopathy, or pancreatic adverse effects ( Moreover, a very recent multicenter, double-blind, randomized, placebo-controlled trial (the SELECT trial), showed that weekly 2.4 mg subcutaneous semaglutide was superior to placebo in reducing the risk of CV death, nonfatal MI, or nonfatal stroke at a mean follow-up of 39.8 months

Hi, everybody

Insurance companies typically do not cover OFF LABEL prescribing of FDA approved for type 2 diabetes for weight loss without a type 2 diabetes diagnosis

& Suzuki, A

This condition increases an individuals chances of adverse cardiovascular events, with research suggesting patients with PAD have an eight times greater risk of cardiovascular death